Shenzhen Xing'er Pharmaceutical Technology Development

Shenzhen Xing'er Pharmaceutical is a clinical-stage biotechnology company based in Shenzhen, China, focused on the development of innovative therapies for ophthalmic diseases. The company specializes in creating small molecule inhibitors that target the vascular endothelial growth factor (VEGF) pathway, aiming to treat conditions such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Its lead candidate, XE-01, is an investigational eye drop formulation designed to provide a non-invasive alternative to traditional intravitreal injections. By leveraging its proprietary R&D platform, Xing'er Pharmaceutical seeks to improve patient outcomes and treatment adherence in the field of ophthalmology. The company has received IND clearance for its lead program in both China and the United States, marking its transition into global clinical development.